Relief Therapeutics Holding SA (RLFTF)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jeremy Meinen CPA | Chief Financial Officer | -- | -- | 1989 |
| Mr. Giorgio Reiner | Chief Scientific Officer | -- | -- | 1965 |
| Mr. Vincenzo Gallo | Head of Legal & Compliance | -- | -- | 1987 |
| Mr. Paolo Galfetti | Chief Business Officer | 632.23k | -- | 1965 |
Relief Therapeutics Holding SA
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 31
Description
Relief Therapeutics Holding SA, a biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for nausea and vomiting associated with radiotherapy-induced, chemotherapy, and postoperative sequels; ACER-001, a sodium phenylbutyrate for the treatment of urea cycle disorders; and PKU GOLIKE for the dietary management of phenylketonuria. It also develops RLF-100, a synthetic form of vasoactive intestinal peptide for the treatment of acute respiratory distress syndrome and certain chronic lung diseases, including sarcoidosis, berylliosis, and checkpoint inhibitor-induced pneumonitis. In addition, the company develops RLF-TD011, a hypochlorous acid solution for epidermolysis bullosa. Further, it is developing RLF-OD32, a next-generation liquid sapropterin formulation for phenylketonuria. Relief Therapeutics Holding SA was founded in 2013 and is based in Geneva, Switzerland.
Corporate Governance
Upcoming Events
April 10, 2025 at 5:01 AM UTC
Relief Therapeutics Holding SA Earnings Date
Recent Events
December 17, 2024 at 12:00 AM UTC
15F-12G: Notice of termination of a foreign private issuer’s registration of a class of securities under Section 12(g)